JP2012507270A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507270A5
JP2012507270A5 JP2011533718A JP2011533718A JP2012507270A5 JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5 JP 2011533718 A JP2011533718 A JP 2011533718A JP 2011533718 A JP2011533718 A JP 2011533718A JP 2012507270 A5 JP2012507270 A5 JP 2012507270A5
Authority
JP
Japan
Prior art keywords
rad35
bioreactor
cells
perfusion system
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507270A (ja
JP5770633B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/064265 external-priority patent/WO2010060719A1/en
Publication of JP2012507270A publication Critical patent/JP2012507270A/ja
Publication of JP2012507270A5 publication Critical patent/JP2012507270A5/ja
Application granted granted Critical
Publication of JP5770633B2 publication Critical patent/JP5770633B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533718A 2008-11-03 2009-10-29 アデノウイルスベクターの産生方法 Expired - Fee Related JP5770633B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19812208P 2008-11-03 2008-11-03
EP08168181.9 2008-11-03
EP08168181 2008-11-03
US61/198,122 2008-11-03
PCT/EP2009/064265 WO2010060719A1 (en) 2008-11-03 2009-10-29 Method for the production of adenoviral vectors

Publications (3)

Publication Number Publication Date
JP2012507270A JP2012507270A (ja) 2012-03-29
JP2012507270A5 true JP2012507270A5 (enExample) 2012-12-13
JP5770633B2 JP5770633B2 (ja) 2015-08-26

Family

ID=40344776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533718A Expired - Fee Related JP5770633B2 (ja) 2008-11-03 2009-10-29 アデノウイルスベクターの産生方法

Country Status (15)

Country Link
US (1) US10041049B2 (enExample)
EP (1) EP2350268B1 (enExample)
JP (1) JP5770633B2 (enExample)
KR (1) KR101504392B1 (enExample)
CN (1) CN102203242B (enExample)
AU (1) AU2009319254B2 (enExample)
BR (1) BRPI0921651A2 (enExample)
CA (1) CA2742474C (enExample)
DK (1) DK2350268T3 (enExample)
EA (1) EA019928B1 (enExample)
ES (1) ES2532015T3 (enExample)
MX (1) MX2011004292A (enExample)
NZ (1) NZ593235A (enExample)
PL (1) PL2350268T3 (enExample)
WO (1) WO2010060719A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
WO2011045381A1 (en) * 2009-10-15 2011-04-21 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
MX2012004222A (es) * 2009-10-15 2012-06-08 Crucell Holland Bv Metodo para purificacion de particulas de adenovirus.
PL2536829T3 (pl) * 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
CN103347595B (zh) 2011-02-10 2016-01-20 克鲁塞尔荷兰公司 气动交变压力膜细胞分离系统
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
KR102044051B1 (ko) 2012-03-12 2019-11-12 얀센 백신스 앤드 프리벤션 비.브이. 터미널 말단이 변경된 재조합 아데노바이러스의 배치
JP5845376B2 (ja) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
PT2988780T (pt) 2013-04-25 2019-03-25 Janssen Vaccines & Prevention Bv Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
BE1022132B1 (fr) * 2013-08-30 2016-02-19 Glaxosmithkline Biologicals S.A. Nouvelle methode.
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3421046A1 (en) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutic hpv16 vaccines
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
AU2016289496B2 (en) 2015-07-07 2021-02-04 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US9663766B2 (en) 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
HK1252967A1 (zh) 2015-08-20 2019-06-06 Janssen Vaccines & Prevention B.V. 治疗性hpv18疫苗
MX2018012094A (es) 2016-04-05 2019-01-10 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
AU2017248018A1 (en) 2016-04-05 2018-09-27 Janssen Vaccines & Prevention B.V. Vaccine against RSV
EP3442688A4 (en) * 2016-04-12 2019-11-20 Artemis Biosystems, Inc. FILTRATION SYSTEMS FOR INFUSION
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
SG11201810078PA (en) 2016-05-30 2018-12-28 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
MX2020004488A (es) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
SG11202003399TA (en) 2017-10-31 2020-05-28 Janssen Vaccines & Prevention Bv Adenovirus and uses thereof
WO2019086450A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
MX421606B (es) 2017-10-31 2025-03-14 Janssen Vaccines & Prevention Bv Vectores adenovirales y usos de estos
AU2018383679C1 (en) 2017-12-11 2026-05-28 Amgen Inc. Continuous manufacturing process for bispecific antibody products
CN110317832B (zh) * 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
WO2019209632A1 (en) 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
PE20211469A1 (es) 2018-11-13 2021-08-05 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
CA3144960A1 (en) * 2019-07-01 2021-01-07 Ology Bioservices, Inc. Method for cultivation of adherent cells in a multiparallel bioreactor
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
CN116867903A (zh) * 2020-12-21 2023-10-10 辉瑞公司 用于改进的细胞转染的方法和系统
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
US20260085096A1 (en) 2022-09-23 2026-03-26 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
EP4590690A1 (en) 2022-09-23 2025-07-30 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
JPWO2024190895A1 (enExample) 2023-03-15 2024-09-19

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04241381A (ja) 1991-01-16 1992-08-28 Brother Ind Ltd 電子学習機
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
JP2000514290A (ja) 1996-07-01 2000-10-31 ローヌ―プーラン・ロレ・エス・アー 組換えアデノウイルスの製造方法
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
KR100918187B1 (ko) 1998-02-17 2009-09-22 쉐링 코포레이션 바이러스를 포함하는 조성물 및 바이러스 제제의 농축방법
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
DE69927013T2 (de) 1998-04-22 2006-06-29 Genvec, Inc. Effiziente reinigung von adenovirus
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AU779267B2 (en) 1998-12-31 2005-01-13 Centelion S.A.S. Method for separating viral particles
CA2364934C (fr) 1999-02-22 2011-10-18 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
ATE519854T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP2420247A1 (en) 2000-03-07 2012-02-22 Merck Sharp & Dohme Corp. Adenovirus formulations
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP1573012B1 (en) 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2519680A1 (en) 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
CN1863918B (zh) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
PL1720972T3 (pl) * 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
CN101001945B (zh) 2004-06-04 2012-02-08 艾克塞勒雷克斯公司 一次性生物反应器系统及方法
US7741099B2 (en) 2004-10-13 2010-06-22 Beth Israel Deaconess Medical Center Inc. Adenoviral vectors and uses thereof
BRPI0518146A (pt) 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
US20080254059A1 (en) 2005-02-11 2008-10-16 Bett Andrew J Adenovirus Serotype 26 Vectors, Nucleic Acid and Viruses Produced Thereby
ATE412737T1 (de) 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
KR20080052512A (ko) 2005-05-23 2008-06-11 박신, 인크. 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
EP1917317A2 (en) 2005-07-22 2008-05-07 Pergo (Europe) AB Flooring system including a dry glue
AU2006279612B2 (en) 2005-08-15 2013-03-21 Altimmune Inc. Immunization of avians by administration of non-replicating vectored vaccines
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
JP5222289B2 (ja) 2006-07-18 2013-06-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
EP2209925A4 (en) 2007-11-14 2017-11-22 Chun-Chieh Chang Method and devices for producing air sensitive electrode materials for lithium ion battery applications
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
HRP20140597T1 (hr) 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
WO2011045381A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
US20120315696A1 (en) 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26

Similar Documents

Publication Publication Date Title
NZ593235A (en) Method for the production of recombinant adenovirus serotype 35
JP2014521353A5 (enExample)
JP2019516410A5 (enExample)
CN102762721B (zh) 用于生产Ad26腺病毒载体的方法
CN103732236B (zh) 用于生产痘苗病毒的方法和组合物
Feuchtinger et al. Adenovirus infection after allogeneic stem cell transplantation
JP2011125348A5 (enExample)
WO2020076820A3 (en) Compositions and methods for preparing viral vectors
JP2009034115A5 (enExample)
JP2004505623A5 (enExample)
JP2004501647A5 (enExample)
JP2005512564A5 (enExample)
JP2006230415A5 (enExample)
JP2013515473A5 (enExample)
CN104812893A (zh) 高感染滴度的细小病毒的生产方法
Dolnik et al. Shedding of Ebola virus surface glycoprotein is a mechanism of self-regulation of cellular cytotoxicity and has a direct effect on virus infectivity
Duffy et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56
JP2013538588A5 (enExample)
CN107523555A (zh) 获得病毒的方法
JP2024504914A5 (enExample)
JP2008508899A5 (enExample)
JP2013537543A5 (enExample)
Pelz et al. Production of antiviral “OP7 chimera” defective interfering particles free of infectious virus
CN103642760B (zh) 一种制备柯萨奇a16型病毒完整实心颗粒的方法
RU2009137571A (ru) Способ наращивания рекомбинантного аденовируса человека